Frontotemporal Dementia Ftd clinical trials

Explore recruiting frontotemporal dementia ftd clinical trials.

Recruiting frontotemporal dementia ftd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Frontotemporal Dementia Ftd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A study to find how well VES001 works and how safe it is in participants with GRN -frontotemporal dementia (GRN-FTD) showing no symptoms

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension

Netherlands, Belgium, Spain, France, Portugal, Italy +1 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

SAD and MAD study of VES001

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

Greece, Germany, Belgium, Italy, Sweden, Portugal +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics of PBFT02 in Adult Participants with Frontotemporal Dementia (FTD) and GRN or C9orf72 Mutations

Portugal, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Frontotemporal Dementia Ftd trials by city

Frontotemporal Dementia Ftd in Toronto Frontotemporal Dementia Ftd in Vancouver Frontotemporal Dementia Ftd in Montreal Frontotemporal Dementia Ftd in Calgary Frontotemporal Dementia Ftd in Edmonton Frontotemporal Dementia Ftd in Ottawa Frontotemporal Dementia Ftd in Winnipeg Frontotemporal Dementia Ftd in Quebec City Frontotemporal Dementia Ftd in Hamilton Frontotemporal Dementia Ftd in Kitchener Frontotemporal Dementia Ftd in London Frontotemporal Dementia Ftd in Halifax Frontotemporal Dementia Ftd in New York Frontotemporal Dementia Ftd in Los Angeles Frontotemporal Dementia Ftd in Chicago Frontotemporal Dementia Ftd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease